comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 23:45:17 - browse：67

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Startup Neumora takes a novel depression drug to Phase 3

leisure time

WSS

Medicare has a new plan to address drug shortages

Startup Neumora takes a novel depression drug to Phase 3

STAT Virtual Event: The State of Biosimilars: What to Watch

CDC overhauls leadership of center that led response to Covid

Doctors find melanoma drugs effective against rare brain cancer

Listen: Wegovy in the brain & pivotal Alzheimer's data

explore

comprehensive

focus

Virginia high school admissions case could be legal follow

Medicare has a new plan to address drug shortages

United colonoscopy coverage change 'may cost lives,' doctors say

Covid's long

United colonoscopy coverage change 'may cost lives,' doctors say

The perfect storm of weather conditions that led to the devastating wildfires in Maui

BioMarin wins approval for gene therapy to treat hemophilia A

Faced with fears of OxyContin misuse, sales reps touted its safety

Alkermes shareholders re

At Orexo, a ‘turning point’ for everything but digital health

hotspot

Listen: Wegovy in the brain & pivotal Alzheimer's data

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Biden tests positive for Covid

WHO calls for emergency meeting on new China virus, as cases spread

Biden tests positive for Covid

At Orexo, a ‘turning point’ for everything but digital health

leisure time

hotspot

focus

focus